The spectrum of PLP1 gene mutations in patients with the classical form of the Pelizaeus-Merzbacher disease. by Hoffman-Zacharska, Dorota et al.
Developmental Period Medicine, 2013, XVII, 4© IMiD, Wydawnictwo Aluna
 !"#$%&!'()*"+*$,&!)()*"+%"!-)#+$.
Dorota Homan-Zacharska1,2, Hanna Mierzewska3, Elżbieta Szczepanik3,  
Jarosław Poznański4, Tomasz Mazurczak3, Anna Jakubiuk-Tomaszuk5, Jacek Mądry6, 
Anatol Kierdaszuk7, Jerzy Bal1
-/$%. $#-!01%&2%PLP1 GENE MUTATIONS 
)*% "-)$*-.%3)-/%-/$%#+"..)#"+%2&!1% 
&2%-/$% $+)4"$0.51$!46"#/$!%7).$".$8
SPEKTRUM MUTACJI GENU PLP1 0% "#9$*-:3%4%;+".'#4*<%
 &.-"#)<%#/&!&6'% $+)4"$0."51$!46"#/$!"
1Department of Medical Genetics; Institute of Mother and Child, Warsaw, Poland
2Institute of Genetics and Biotechnology; Warsaw University, Poland
3Clinic of Neurology for  Children and Adolescents; Institute of Mother and Child, Warsaw, 
4Department of Biophysics; Institute of Biochemistry and Biophysics, Polish Academy of  Sciences, Warsaw, 
5Department of Clinical Genetics, Medical University of Bialystok, Poland
6Department of Neurology, Faculty of Health Science, Warsaw Medical University
7Clinic of Neurology for Children and Adolescents, Provincial Hospital in Biala Podlaska
Abstract
The Pelizaeus-Merzbacher disease (PMD) is a rare X-linked recessive hypomyelination disorder caused 
by mutations of the proteolipid protein1 gene (PLP1). There is a spectrum of PLP1-related disorders from 
very severe connatal PMD, through classical PMD to mild spastic paraplegia type 2 (SPG2), with some 
correlation between the type of mutation and the phenotype. In general, missense mutations give rise 
to more severe forms of the disease, deletions and null mutations to mild PMD and SPG2. The most com-
mon variations, duplications, result in the classical-intermediate form of PMD.
The aim: To  report the analysis of mutations in the PLP1 gene and phenotype di!erences in ten male pa-
tients diagnosed with PMD. Although they had di!erent types of PLP1 mutations (duplications, missense 
and nonsense mutations), all of them were clinically classi"ed with the classical form of PMD (clPMD).
Material and methods:  The subjects of analysis were ten male patients aged 1.5 to 21 years who were 
diagnosed with PMD. All patients developed the "rst clinical symptoms between 1 an 8 months of age 
and showed developmental delay, mainly in motor skills. All were classi"ed with the classical form of the 
disease, according to international clinical criteria and the electrophysiological and brain MRI criteria of 
hypomyelination. The molecular analysis of the PLP1 gene involved dosage analysis and direct sequenc-
ing of all exons and promotor region of the gene.
Results: The clinical diagnosis of PMD was con"rmed for all subjects by molecular analysis of the PLP1 
gene. Although all had the classical form of PMD, it was caused by mutations of di!erent types: duplica-
tions of the entire gene, missense and nonsense mutations. 
Conclusions: Our clinical and molecular "ndings showed that the phenotypic spectrum resulting from 
PLP1 mutations seems to be broader in patients with the PLP1 gene duplication compared to patients 
with both nonsense and missense mutation. Nevertheless, apart from the type of mutation, all our pa-
tients’ clinical manifestation falls into the category of the classical form of PMD according to interna-
tional criteria. Obviously the type of mutations, but also other unidenti"ed factors may a!ect the clinical 
course of PMD. 
Key words: gene duplication, hypomyelination disorder, leukodystrophy, Pelizaeus-Merzbacher 
disease, PLP1, point mutations
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Streszczenie
Choroba Pelizaeusa-Merzbachera (ang. Pelizaus-Merzbacher Disease, PMD) jest rzadką , dziedziczoną 
jako cecha recesywna, sprzężona z płcią, chorobą hipomielinizacyjną, której podłoże molekularne 
stanowią mutacje genu PLP1. Choroby powodowane mutacjami tego genu określane są jako tzw. 
choroby PLP1-zależne i stanowią spektrum jednostek od ciężkiej, wrodzonej postaci PMD przez 
klasyczną PMD do spastycznej paraplegii typu 2 (ang. Spastic Paraparesis type 2, SPG2) o łagodniejszym 
przebiegu, charakteryzujących się częściową korelacją pomiędzy typem mutacji w genie a fenotypem. 
W większości przypadków mutacje missens stanowią podłoże najcięższych postaci choroby, delecje i 
mutacje typu „null” lżejszych postaci PMD i SPG2. Najczęstsze mutacje, duplikacje genu powodują 
wystąpienie klasycznej postaci PMD.
Cel pracy: Przedstawienie wyników analizy zmienności fenotypowej w kontekście podłoża molekular-
nego-mutacji genu PLP1 u dziecięciu pacjentów płci męskiej ze zdiagnozowaną PMD. Wszyscy zostali 
zakwali"kowani jako pacjenci z klasyczną postacią choroby, pomimo, że w genie PLP1 zidenty"kowano 
u nich mutacje różnego typu (duplikacje, mutacje punktowe typu missens i nonsens).
Materiał i metody: Dziesięciu pacjentów płci męskiej w wieku od 1,5 do 21 lat  z rozpoznaną klasycz-
na postacią PMD zdiagnozowaną zgodnie z międzynarodowymi kryteriami klinicznymi oraz elektro"-
zjologicznymi i neuroobrazowymi kryteriami hipomielinizacji. Analiza molekularna genu PLP1 objęła 
badania dawki genu, jak również bezpośrednie sekwencjonowanie wszystkich eksonów i obszaru pro-
motorowego genu.
Wyniki: Rozpoznanie kliniczne PMD, zostało u  pacjentów potwierdzone badaniem molekularnym 
genu PLP1. Pomimo, że u wszystkich badanych stwierdzono klasyczną postać PMD to jej przyczyną były 
mutacje różnego typu; duplikacje całego genu, zmiany typu missens i nonsens.
Wnioski: Zmienność fenotypowa wydaje się być większa u pacjentów z duplikacją genu PLP1 w porów-
naniu z pacjentami, u których zidenty"kowano mutacje typu missens i nonsens. Pomimo to, niezależnie 
od typu mutacji, obraz kliniczny wszystkich badanych odpowiadał cechom klasycznej postaci PMD.
Słowa kluczowe: choroba Pelizaeusa-Merzbachera, choroby hipomielinizacyjne, duplikacja genu, 
leukodystro!a, mutacje punktowe, PLP1
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INTRODUCTION
!e Pelizaeus-Merzbacher disease (PMD; MIM 
312080) is a rare form of inherited leukodystrophies – 
diseases a"ecting the white matter of the central nervous 
system (CNS). PMD is classi#ed as a hypomyelinating 
disorder (1), inherited as an X-linked recessive trait 
and is caused by mutations in the PLP1 gene (MIM 
300401) localized in locus Xq22. !e gene encodes the 
proteolipid protein 1 (PLP1) and its smaller, di"erently 
spliced form DM20 (2). !e PLP1/DM20 is the major 
component of the oligodendrocytes’ myelin in CNS, 
where it may stabilize and maintain the myelin sheath (2, 
3). DM20 expression can be detected in the early stages 
of CNS development, before the onset of myelination, 
and this isoform is probably involved in oligodendrocyte 
di"erentiation (4). !e DM20 form lacks 35 PLP-speci#c 
amino acids and is not able to compensate for the loss 
of proteolipid protein in myelin (5,6). 
Mutations in the PLP1 gene cause two allelic disorders, 
PMD and SPG2 (MIM 312920), characterized by a wide 
clinical spectrum, from severe connatal and classic 
PMD to “uncomplicated” and  “complicated” forms of 
SPG. Generally the PMD/SPG2 phenotype variability 
is not completely understood. However, because of the 
intrafamilial heterogeneity of the disease’s severity, not 
only the type of mutation and its localization in the 
PLP1 gene, but also the in$uence of modi#er genes may 
play a role in the #nal clinical phenotype. PLP1/DM20 
expression not only in oligodendrocytes, but also in 
Schwann cells and neurons (motor, cortical, brainstem) 
may have relevance for the phenotypic variability of 
PLP1-related disorders.
!e aim is to report the analysis of mutations in 
the PLP1 gene and phenotype di"erences in ten boys 
diagnosed with PMD. Although they had di"erent types 
of PLP1 mutations (duplications, missense and nonsense 
mutations), all of them were classi#ed clinically with the 
classical form of PMD (clPMD).
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10 male patients aged from 1.5 to 21 y. with suspicion 
of PMD  (7 unrelated probands, 2 a"ected brothers and 1 
cousin) were referred for PLP1 gene analysis. !e patients 
presented the classical form of PMD according both to 
the international clinical criteria (onset within the #rst 
5 years of life with the nystagmus occurring within the 
#rst 2 months of age, initial hypotonia followed by spastic 
quadriparesis, ataxia, titubation, dystonia, athetosis, and 
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!e PLP1 dosage analysis was performed for all 
probands by Multiple Ligation-dependent Probe 
Ampli#cation reaction (MLPA) using the tests SALSA 
P022 A1 or B1 and P071 (MRC-Holland), containing 
probes covering all PLP1 exons and 20 di"erent regions 
for the Xq22.2 (11). Reactions were performed according 
to the manufacturer’s recommendations (100 ng of DNA/
reaction, hybridization time 16 h and 35 PCR cycles). 
Reaction products were separated with 3130 Genetic 
Analyzer (Applied Biosystems). We used Gene Marker 
v.1.51 so%ware (So%Genetics LLC) to dosage ratio analysis 
(standard parameters, dosage ratio boundaries <0.75 
and >1.25 for deletion and duplication respectively). 
For the patients without PLP1 duplications, the 
presence of the point mutations was analyzed. !e 
direct sequencing of all 7 exons and the promoter region 
of the PLP1 gene, according to Osaka et al. 1999 (12), 
were performed. Sequencing was performed using 
the BigDye v.3.2 terminator sequencing kit (Applied 
Biosystems), reaction products run on an ABI 3130 
Genetic Analyzer, data analyzed with MutationSurveyor 
V3.24 so%ware (So%Genetics LLC). For the two new 
missense mutations, 100 healthy males were examined 
to determine the frequency of this mutation in the 
control population. 
!e identi#ed variants were labelled according to the 
PLP1 reference sequence NM_000533.3 (NCBI RefSeq; 
http://www.ncbi.nlm.nih.gov/nuccore). !e impact of 
missense mutations on protein structure and function 
were analysed by PolyPhen-2 v.2.1 so%ware, HumVar 
model (13) [http://genetics.bwh.harvard.edu/pph2] and 
MutPred tool (14) [http://mutpred.mutdb.org]. 
RESULTS
HEGDG=AE$A?I<=>?$
!e #rst clinical signs and symptoms were observed 
between 1 and 8 months of age in all 10 patients. 
Developmental delay, mainly in motor skills was noted 
in all cases. Nystagmus was also a constant #nding as well 
as mainly axial muscular hypotonia presented during 
the #rst 1-2 years of age. In patients who achieved head 
control, nystagmus was accompanied by head nodding 
(spasmus nutans). !e symptoms showed a tendency to 
alleviate with age. Mild stridor was noted at infancy in 
5 out of 10 patients, in two of them only during crying. 
Spastic progressive paraplegia was visible a%er the age of 
2-4 years in all patients but one (F05_IV-2). He presented 
cerebellar ataxia regarded as cerebral palsy up to the age of 
8 years. By the age of 2-4 years, six patients also revealed 
symptoms of cerebellar ataxia and dyskinesias, mainly of 
choreoatetotic type. In older patients choreoathetosis was 
dismissed, while  focal or multifocal dystonia developed, 
frequently induced by movements and overlapping with 
spasticity. !e intellectual level ranged from severe mental 
retardation to normal IQ. Only one patient (F05_IV-2) 
achieved temporarily autonomous walking as a teenager, 
but a%er the age of 20 his neurological state deteriorated 
markedly. He also achieved comprehensive but mildly 
JGK#$-#$%<LGKM<<?$CN$>O<$%) $NA@GEG<?$IM<?<D><L#
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cognitive impairment) and to the electrophysiological and 
brain MRI criteria of hypomyelination (mild hyperintensity 
on T2, combined with normal signal on T1 and highly 
abnormal, hyperintensive signal on FLAIR sequences) (7, 
8, 9,10). !e severity of the clinical picture was assessed 
according to a 0-4 degree scale based on the best motor 
function the patients were able to achieve up to 10 years: 
from 0 – patients with no motor achievement; 1 – patients 
who achieved head control between 2-4 yrs; 2 – patients 
who were able to achieve the sitting position between 3-5 
yrs, and might achieve dysarthric but comprehensible 
speech; 3 – patients who achieved the sitting position 
between 1-2 yrs of age and walked with support at 2-6 yrs, 
but lost this capacity between 14-20 yrs of age,  achieved 
dysarthric but comprehensible speech; 4 – patients who 
were walking independently (8).
 63$?A@IE<?
DNA analysis was performed for 20 subjects: 7 PMD 
probands and their healthy and a"ected relatives. In two 
cases molecular diagnosis was performed in secondary 
laboratories (Institute fur Human Genetics in Hamburg, 
Klinisch Genetisch Centrum Nijmegen). To con#rm the 
nature of the identi#ed mutation, inherited vs. de novo, we 
performed the carrier test for all the patients’ mothers and 1 
grandmother. !e carrier status was also tested in 8 women 
at risk. In 1 case a prenatal diagnosis was performed (Fig. 1).
!e healthy control group consisted of 100 unrelated 
males 20-73 years old; mean 29.9 [SD± 9.7]. All DNA 
samples were obtained with written informed consent. 
!e Institute of Mother and Child Ethics Committee 
approved the study. 
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dysarthric speech and attended a mainstream secondary 
school and started to study at university.
All patients underwent brain MRI examination 
that revealed di"use symmetrical central white matter 
hypomyelination. Brainstem evoked potentials revealed 
severely prolonged central latencies in all the patients. 
One of the patients’ mothers (F01_I-2), being a 
carrier of the point terminating mutation p.Gln129*, 
was symptomatic. !is 26-year old woman presented 
cognitive dysfunction, nystagmoid eye movements, slowly 
progressive dysartria, spastic paraparesis and cerebellar 
signs. Her MRI examination of the brain revealed abnormal 
di"use hypo/dysmyelination of cerebral white matter.
)CE<=9EAM$ADAEF?G?
!e clinical diagnosis of PMD was con#rmed for all 
subjects by molecular analysis of the PLP1 gene. !e 
probands, representing 7 families, have changes of di"erent 
types: duplications of the entire gene (43%) missense  (43%) 
and nonsense (14%) mutations. Duplications of the X 
chromosome segments, encompassing the PLP1 gene, were 
identi#ed in 3 families (4 patients – 2 unrelated subjects, 
2 brothers, Fig. 1 F03, F05 and F06). All duplications 
were inherited from asymptomatic carrier mothers.
!e nonsense mutation p.Gln129* (c.385C>T), 
already described as causing PMD  (p.Gln128Term) (15), 
was found in one family in two a"ected boys and their 
symptomatic mother, diagnosed with SPG (Fig.1 F01). 
Di"erent missense mutations were identi#ed in three 
families (Fig. 2 F07, F28 and F32), one already known 
- p.Val209Asp (c.626T>A) (16) and two not reported 
previously – p.Ile47!r (c.140 T>C) and p.Ala88Asp 
(c.263C>A). In silico analysis using the PolyPhen-2 tool 
con#rmed the potential pathogenicity of both of them. 
Both were predicted as probably damaging with the 
p.Ile47!r score of 0.882 and p.Ala88Asp 0.956. !e 
MutPred tool, giving the general scores of deleterious e"ect 
probabilities, 0.832 and 0.852 respectively, con#rmed these 
data. !e substitutions c.140 T>C and c.263C>A were 
not identi#ed in the examined healthy male cohort (100 
alleles). According to the analysis done with the aid of the 
GPS server (GPS 2.0), !r49, located in the extracellular 
loop A (Fig.2) is a putative target for CAMK/CAMKL/
LKB human kinases (17). !e replacement Ile47!r 
visibly reduces the score for the !r49 phosphorylation 
(8,59 down to 5.82). Moreover, !r47 itself becomes a 
putative target for STE/STE7/MAP2K1 and STE/STE7/
MAP2K2 kinases. In view of the above data, the Ile47!r 
replacement may change the phosphorylation pattern 
of loop A, and in consequence may modify the PLP1 
functionality. 
According to the proposed topology of PLP1 (Fig. 2), 
the Ala88 residue is located in the proximity of the internal 
side of the cellular membrane. !e Ala88Asp replacement 
creates unfavourable interactions between side chains 
of Asp88 and Glu89, resulting in the reorientation of 
transmembrane helix TM2 and/or in a distortion of the 
proximal region of the cellular membrane. Both should 
a"ect the organisation of the core framework of four 
transmembrane helices (TM1-TM4) of PLP1, and thus 
interfere with its biological function.
!e clinical, neurological, MRI and molecular 
characterization of the patients is presented in Table I.
JA@GEF$?>9LG<?
!e PMD carrier status causing mutations was analysed 
in the mothers of all the probands and revealed that de 
novo mutation only occurred in the family F32. In the 
family F01 the prenatal test was proposed, revealing that 
the male foetus was a carrier of PLP1 mutation identi#ed 
in the family. In three families (F06, F07 and F32), all 
the sisters of the probands’ mothers decided to de#ne 
their mutation carrier status, so appropriate analysis 
was performed depending on the type of mutation in 
the families (F06 MLPA analysis, F07 and F032 direct 
sequencing of exons 2 and 6 respectively) (Fig. 1).
DISCUSSION
Mutations of the PLP1 causing PMD/SPG2 fall into two 
categories, the gene rearrangements (mainly duplications) 
and sequence variations, which account for 50-60% and 
15-25% of the cases, respectively (7).  Genotype-phenotype 
correlations are in some degree associated: the missense 
mutations, if localised in highly conserved regions, cause 
the most severe form of PMD, deletions and null mutations 
lead to a mild form of PMD and SPG2 presenting with 
peripheral neuropathy. !e duplications result in the classical-
JGK#$+#R$HOAMA=><MGSABCD$CN$>O<$PLP1$ICGD>$@9>ABCD?$GL<DBT<L$
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ADL$5[X$ADL$CD<$=F>CIEA?@G=$V5HX$ECCI?#$4O<$%5%-W?I<-
=GT=$.\$A@GDC$A=GL?$M<KGCD$VA:?<D>$GD$ )+,X$G?$IAM>$CN$
>O<$=F>CIEA?@G=$ECCI]$GD$ECCI$[$>YC$LG?9EIOA><$:MGLK<?$
AM<$EC=AEGS<L$V:A?<L$CD$>CICECKF$:F$^<G@?$ADL$8>C_<E*$
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form (scores 2,3) in partially conserved and SPG (score 
4) in non-conservative regions of PLP1. New identi#ed 
substitutions p.Ile47!r and p.Ala88Asp, giving a very 
similar phenotype, a"ect non-conservative aa 47 and 
highly-conservative aa 88. !e Ile47 is localized in 
the extracellular loop A. Based on data showing that 
substitutions of neighbouring, also non-conservative, 
Leu46 (Leu46Pro and Leu46Arg) result in severe 
PMD (8), we can assume that any changes in this loop 
may be deleterious. !e aa Ala88 is localised in the 
transmembrane domain. !e substitution Ala88Asp 
may a"ect its structure/function. !e third identi#ed 
substitution p.Val209Asp lies in the extracellular loop B, 
where two cysteine-mediated disul#de bridges, playing 
an important role in correct PLP1 folding, are localized. 
Mutations in this loop are ”over-represented” among 
PLP1 missense mutations, suggesting its important role 
in proper protein folding. Generally the pathogenic 
mechanism of missense mutations in PLP1 is thought 
to be due to the accumulation of the miss-folded protein 
in the rough endoplasmatic reticulum (ER) and failure 
in its transport to the cell membrane. Depending 
on the  localization of the substitution, miss-folded 
protein can reach the ER or the endosomal/lysosomal 
compartment, which can be correlated with severe 
and mild phenotypes, respectively. In both cases the 
death of oligodendrocytes results from the induction 
of the unfolded protein response (UPR) followed by 
the activation of chaperone genes and apoptosis (24). 
!is is one of the postulated mechanisms of PMD/SPG 
pathogenesis. In the case of PLP1 duplications, protein 
overexpression causes its accumulation in endosome/
lysosome, aberrant protein transport and myelin assembly 
(25). Clinical manifestation varied between patients 
with gene duplication but in general they show the 
clPMD, which is o%en milder than in patients with point 
mutations. However, among our patients with PLP1 
duplication, we can observe nearly the full spectrum 
of disease severity forms (1/2, 2, 3 and even 4). !is 
indicates that even for best-known mutations, such as 
PLP1 duplication, it is very di?cult to predict the course 
of the disease, but on the other hand molecular analysis 
of PLP1 may result in the expansion of the disease 
phenotype to less typical patients. At this moment the 
PLP1 diagnostic test (duplication/deletion and sequence 
analysis) makes it possible to con#rm the diagnosis for 
about 60% of male patients, the remaining 40% do not 
have identi#able PLP1 mutations (7). !ese data suggest, 
that the mutation may occur in regions of the gene not 
routinely analysed (upstream/downstream sequences and 
introns) but also indicate genetic heterogeneity in the 
group of hypomyelinating leukodystrophies (HMLs). PMD 
caused by PLP1 mutations is a prototype of the HMLs 
describedin OMIM classi#cation as hypomyelinative 
leukodystrophy type 1 - HLD1. Other forms include: 
HLD2 (known as Pelizaeus-Merzbacher Like Disease 
1; MIM 608804) autosomal recessive form caused by 
mutations in GJC2 gene (MIM 608803), HLD3 (MIM 
260600) autosomal recessive caused by mutations in 
AIMP1 gene (MIM 603605), HLD4 (MIM612233) also 
known as autosomal recessive mitochondrial Hsp60 
intermediate form of PMD, triplication in a much more 
severe form (18). !ese genotype-phenotype correlations 
may be explained by distinct mutational mechanisms at 
the cellular level (19, 20, 3).
In this study we describe a group of patients with 
the classical PMD, despite di"erent types of the PLP1 
gene mutations. !ere were no di"erences among the 
groups with respect to the age of the patients at the time 
of the disease’s onset, and the types of the #rst signs and 
symptoms of the neurological status in the course of 
the diseases.  !ere was, however, a di"erence between 
the groups regarding the range of PMD severity score 
and their cognitive level. We observed intra-familial 
heterogeneity of phenotype (Fig.1). Such data may 
con#rm the hypothesis of the involvement of modifying 
genes in the #nal phenotype, especially in patients with 
PLP1 duplications. !e X-chromosome submicroscopic 
duplications in region Xq22.2 including the entire PLP1 
gene, are the most common reason for PMD (7). !e 
range of duplication segments is variable in size, and 
each duplication event seems to be unique – family 
speci#c (21). 
In the group of our probands, the frequency of point 
mutations was even a little higher than of duplications 
(57 vs 43%), but we have to keep in mind the limitations 
of interpretation due to the group size. Among patients 
with point mutations we identi#ed one case of a nonsense 
change p.Gln129*, in two a"ected brothers and their 
symptomatic mother (F01, Fig. 1). !is truncating mutation 
is localized to the PLP-speci#c cytoplasmatic loop of the 
protein and alters the PLP1 but retains the DM20 form 
(Fig. 2). !is kind of mutation was described in atypical 
mild forms of PMD, which suggested the protective 
role of the DM20 isofom (22). However, it seems not 
to be the case, as other patients with much more severe 
forms of PMD, carrying this type of mutation have also 
been described. Among them there was a family with 
p.Gln129* where, as presented in F01, all the a"ected 
boys had clPMD and all female mutation carriers were 
symptomatic, with progressive disease of later onset 
(23). !is and our data are contradictory to the others, 
suggesting that there is a risk of being the symptomatic 
mutation carrier for women in families only with a mild 
form of PMD (16). 
Missense mutations identi#ed in three families were 
localized in di"erent parts of the PLP1 (Fig. 2), two of 
them in the extracellular loops of the protein, p.Ile47!r 
in loop A and p.Val209Asp in loop B.  Substitution 
p.Val209Asp was described for clPMD (17), p.Ile47!r 
and p.Ala88Asp, located in the transmembrane domain 
(TM), have not been reported previously. Mutation 
p.Ile47!r cosegregates with the PMD phenotype in 
family (F07, Fig1), p.Ala88Asp arose de novo (the only 
one case among patients, 14%). If we try to #t our data 
into the scheme of genotype-phenotype correlation in 
PLP1-related disorders proposed by Callioux and co-
workers (8) we see that most patients classi#ed with 
score 2 have point mutations in the gene. !e phenotypic 
presentation of a missense mutation depends on its 
location. !e most severe forms of PMD (scores 0,1) 
result from mutations in highly conserved, the mild 
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chaperonopathy, caused by mutation in HSPD1 gene 
(MIM118190), HLD5 (MIM 610532) linked to FAM126A 
gene (MIM 610531), HLD6 (MIM 612438) identi#ed 
on a clinical basis and linked to TUBB4A gene (MIM 
602662), HLD7 (MIM 607692) and HLD8 (OMIM 
614381) both autosomal recessive, caused by mutations 
in POLR3A (MIM 614258) and POLR3B (MIM614366) 
genes coding the 2 largest subunit of RNA polymerase III. 
!is group also includes the X-linked Allan-Herndon-
Dudley syndrome (MIM 300523) caused by mutation 
in the SLC16A2 gene (MIM 300095) [7, 25].
CONCLUSIONS
Our clinical and molecular #ndings showed that the 
phenotypic spectrum resulting from PLP1 mutations seems 
to be broader in patients with the PLP1 gene duplication 
compared to the patients with both nonsense and missense 
mutation. Nevertheless, apart from the type of mutation, 
all our patients’ clinical manifestation falls into the category 
of the classical form of PDM according to international 
criteria. Obviously, some factors discussed above and 
also unidenti#ed ones a"ect the clinical course of PMD. 
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